BridgeBio Pharma, Inc.

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

BBIO$78.67+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Revenues:
Net product revenue	$222,440	$71,501	$403,036	$108,240
License and services revenue	5,804	37,440	10,223	117,130
Royalty revenue	15,432	1,624	24,932	1,828
Total revenues, net	243,676	110,565	438,191	227,198
Operating costs and expenses:
Cost of revenues:
Cost of goods sold	10,528	2,848	18,260	4,882
Cost of license, services, and royalty revenue	4,518	805	6,725	1,410
Total cost of revenues	15,046	3,653	24,985	6,292
Research and development	149,448	111,231	276,084	222,662
Selling, general and administrative	186,261	129,154	350,157	235,519
Restructuring, impairment, and related charges	—	805	—	1,375
Total operating costs and expenses	350,755	244,843	651,226	465,848
Loss from operations	(107,079)	(134,278)	(213,035)	(238,650)
Other income (expense), net:
Interest income	6,659	3,898	12,905	9,283
Interest expense	(13,278)	(11,607)	(26,220)	(29,728)
Noncash interest expense on deferred royalty obligations (1)	(41,345)	(26,030)	(81,218)	(50,050)
Loss on extinguishment of debt	—	—	—	(21,155)
Net loss from equity method investments	(6,435)	(20,189)	(24,718)	(35,745)
Other income, net	5,587	6,548	9,840	14,779
Total other expense, net	(48,812)	(47,380)	(109,411)	(112,616)
Loss before income taxes	(155,891)	(181,658)	(322,446)	(351,266)
Provision for income taxes	—	2,100	—	2,100
Net loss	(155,891)	(183,758)	(322,446)	(353,366)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests	3,675	1,855	6,187	4,041
Net loss attributable to common stockholders of BridgeBio	$(152,216)	$(181,903)	$(316,259)	$(349,325)
Net loss per share attributable to common stockholders of BridgeBio, basic and diluted	$(0.78)	$(0.95)	$(1.62)	$(1.84)
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic and diluted	195,785,884	190,517,215	195,290,642	190,332,261

(1)Including related party amounts of $(5,575) and $(10,936), respectively, for the three and six months ended June 30, 2026 (as described in Note 9).

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.